Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
Completed without a posted recruiting period
Chipscreen Biosciences, Ltd.Not applicable NCT07519265 Registry history of NCT07519265 on ClinicalTrials.gov (opens the registry)
2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.
Completed without a posted recruiting period
Chipscreen Biosciences, Ltd.Not applicable NCT07519265 Registry history of NCT07519265 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Also in this update: Primary completion date changed from estimate of Jun 29, 2026 to May 26, 2026
Chipscreen Biosciences, Ltd.Not applicable NCT07412015 Registry history of NCT07412015 on ClinicalTrials.gov (opens the registry)
| Phase 1 | 5 | |
| Phase 1/2 | 1 | |
| Phase 2 | 1 | |
| Phase 3 | 4 |
Pancreatic Cancer (3) · Diabetes (2) · Lung Cancer (2) · Non-Hodgkin Lymphoma (2) · Type 2 Diabetes (2) · Colorectal Cancer (1) · DLBCL (1) · Glioblastoma (1) · Glioma (1) · Non-Small Cell Lung Cancer (NSCLC) (1)